L&P's Client Argentum Pharmaceuticals and Eli Lilly Settle Patent Dispute over Cialis® Drug
Argentum Pharmaceuticals LLC, a generic pharmaceutical company represented by Laurence & Phillips IP Law (L&P), reached a settlement and license agreement with Eli Lilly and Company related to Argentum’s generic version of Eli Lilly and Company’s Cialis® (tadalifil) drug. The agreement generally provides that Argentum may commence marketing its generic product no earlier than September 27, 2018. The settlement agreement followed the filing of a petition for an inter partes review of U.S. Patent No. 6,943,166, which claims a method of treating sexual dysfunction in a patient with a compound having a structure as shown below.
